Snowden Capital Advisors LLC Lowers Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Snowden Capital Advisors LLC trimmed its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 6.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,596 shares of the medical equipment provider's stock after selling 533 shares during the period. Snowden Capital Advisors LLC's holdings in Intuitive Surgical were worth $3,965,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Essex Savings Bank boosted its holdings in Intuitive Surgical by 22.9% in the 4th quarter. Essex Savings Bank now owns 660 shares of the medical equipment provider's stock worth $344,000 after buying an additional 123 shares during the period. Outlook Wealth Advisors LLC boosted its holdings in Intuitive Surgical by 7.1% in the 4th quarter. Outlook Wealth Advisors LLC now owns 437 shares of the medical equipment provider's stock worth $228,000 after buying an additional 29 shares during the period. Carnegie Investment Counsel boosted its holdings in Intuitive Surgical by 33.3% in the 4th quarter. Carnegie Investment Counsel now owns 653 shares of the medical equipment provider's stock worth $341,000 after buying an additional 163 shares during the period. Ritholtz Wealth Management boosted its holdings in Intuitive Surgical by 1.0% in the 4th quarter. Ritholtz Wealth Management now owns 4,465 shares of the medical equipment provider's stock worth $2,331,000 after buying an additional 44 shares during the period. Finally, JGP Wealth Management LLC boosted its holdings in Intuitive Surgical by 2.1% in the 4th quarter. JGP Wealth Management LLC now owns 2,095 shares of the medical equipment provider's stock worth $1,094,000 after buying an additional 44 shares during the period. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other Intuitive Surgical news, EVP Robert Desantis sold 11,545 shares of the business's stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $499.22, for a total transaction of $5,763,494.90. Following the sale, the executive vice president now owns 5,224 shares of the company's stock, valued at approximately $2,607,925.28. The trade was a 68.85% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Fredrik Widman sold 810 shares of the firm's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $573.78, for a total transaction of $464,761.80. Following the completion of the transaction, the vice president now directly owns 473 shares of the company's stock, valued at approximately $271,397.94. This represents a 63.13% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 32,700 shares of company stock worth $16,865,621. Corporate insiders own 0.70% of the company's stock.

Intuitive Surgical Stock Down 0.8%

Intuitive Surgical stock traded down $4.47 during midday trading on Tuesday, reaching $557.16. The stock had a trading volume of 1,233,924 shares, compared to its average volume of 1,644,792. Intuitive Surgical, Inc. has a 52-week low of $396.15 and a 52-week high of $616.00. The firm has a market cap of $199.70 billion, a price-to-earnings ratio of 86.92, a price-to-earnings-growth ratio of 5.85 and a beta of 1.70. The company has a fifty day moving average of $506.50 and a 200 day moving average of $537.23.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last posted its quarterly earnings data on Tuesday, April 22nd. The medical equipment provider reported $1.81 earnings per share for the quarter, topping analysts' consensus estimates of $1.71 by $0.10. The company had revenue of $2.25 billion for the quarter, compared to analyst estimates of $2.19 billion. Intuitive Surgical had a net margin of 27.81% and a return on equity of 14.55%. During the same period in the prior year, the company posted $1.50 EPS. Equities research analysts predict that Intuitive Surgical, Inc. will post 6.43 EPS for the current year.

Analyst Ratings Changes

ISRG has been the subject of several research reports. Citigroup increased their price objective on shares of Intuitive Surgical from $640.00 to $711.00 and gave the company a "buy" rating in a report on Friday, January 24th. Bernstein Bank increased their price objective on shares of Intuitive Surgical from $655.00 to $700.00 and gave the company an "overweight" rating in a report on Monday, January 27th. UBS Group increased their price objective on shares of Intuitive Surgical from $500.00 to $560.00 and gave the company a "neutral" rating in a report on Monday, January 27th. Royal Bank of Canada dropped their price objective on shares of Intuitive Surgical from $630.00 to $605.00 and set an "outperform" rating for the company in a report on Wednesday, April 23rd. Finally, JPMorgan Chase & Co. increased their price target on shares of Intuitive Surgical from $575.00 to $675.00 and gave the company an "overweight" rating in a report on Friday, January 24th. Five equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $598.95.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.